Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
BioSeeker Group AB
January 30, 2012 4763 Pages - SKU: BIOS6796054
|
|
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publication:
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized."
|
- Key Topics Covered:
- Part I: Apoptosis
- 5.1 The Scope of this Report 33
- 6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
- 9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
- Disclaimer 1602
- 11 Drug Index 1603
- 12 Company Index 1611
- Figures: Includes 7 Figures
- Tables: Includes 315 Tables
- Total Number of Pages: 1,617
- Part II: Angiogenesis
- 5.1 The Scope of this Report 37
- 6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
- 8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
- 9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
- 12 Drug Index 1687
- 13 Company Index 1697
- Figures: Includes 7 Figures
- Tables: Includes 310 Tables
- Total Number of Pages: 1,704
- Part III: Protein Kinase Inhibitors
- 5.1 The Scope of this Report 30
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets) 36-336
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407
- 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies) 408-495
- 9 Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications) 496-649
- 10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators) 650-1417
- 12 Drug Index 1419
- 13 Company Index 1433
- Figures: Includes 6 Figures
- Tables: Includes 302 Tables
- Total Number of Pages: 1442
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
